AGNPF

Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals CEO To Deliver Virtual Keynote Presentation on Company’s DMT Program at the International Microdose DMT Conference

VANCOUVER, British Columbia, Sept. 09, 2021 -- Algernon Pharmaceuticals Inc.ย (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the โ€œCompanyโ€ or โ€œAlgernonโ€) a clinical stage pharmaceutical development company, is pleased to announce that its CEO Christopher J. Moreau will be delivering the Keynote Presentation at the Microdose Virtual 2021 โ€œThe ... Read More...

Algernon Pharmaceuticals Confirms DMT Increased Growth of Neurons by 40% in Preclinical Study at Sub Hallucinogenic Dose

VANCOUVER, British Columbia, Sept. 07, 2021 -- Algernon Pharmaceuticals Inc.ย (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the โ€œCompanyโ€ or โ€œAlgernonโ€) a clinical stage pharmaceutical development company, is pleased to announce that it has confirmed in its own preclinical study, that AP-188 (โ€œN,N-Dimethyltryptamine or โ€œDMTโ€), increased the ... Read More...